BIOLOGICAL · Unmapped registry intervention
trastuzumab
Find medicine records ·
Find other trials using this name
Clinical trial
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00003881
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTrastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lung Cancerverified · MONDO: lung cancer
Interventions
trastuzumabBIOLOGICAL
carboplatinDRUG · verified · RxNorm: carboplatin
paclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Eastern Cooperative Oncology Grouplead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
PhiladelphiaPennsylvania, United States4New YorkNew York, United States2BostonMassachusetts, United States2ChicagoIllinois, United States2NashvilleTennessee, United States2ClevelandOhio, United States2PittsburghPennsylvania, United States2TampaFlorida, United States2IndianapolisIndiana, United States2New OrleansLouisiana, United States2MilwaukeeWisconsin, United States2MadisonWisconsin, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00003881 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.